Atezolizumab plus bevacizumab was recently approved as first-line systemic therapy for patients with advanced HCC. Read an expert’s thoughts how this new approach will fit into contemporary treatment paradigms.
When should patients with HCC be transitioned from locoregional to systemic therapy to maximize therapeutic benefit? In this commentary, HCC expert Richard Finn, MD, provides his thoughts on this important question.
Review expert insights into the selection of optimal systemic treatment for patients with advanced HCC and Child-Pugh B liver disease.
Download this short summary slideset of key takeaway points on using systemic therapy for patients with advanced HCC.
Download this slideset for expert perspectives on best practices and emerging strategies in treating patients with advanced HCC.
Watch this on-demand Webcast capturing a live CCO Webinar featuring expert presentation on key data and treatment paradigms for advanced HCC.
For further information concerning Lilly grant funding visit www.lillygrantoffice.com.